美国FDA-话题@MedSci - 梅斯（MedSci）

#美国FDA#

186篇内容 | 3748人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1551362, encodeId=19c01551362cc, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA一个月内批准的第二个抗菌素新药Sivextro预示抗生素新药研发的春天？, objectType=article, longId=36854, objectId=1ac13685437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ac13685437, replyNumber=0, likeNumber=90, createdTime=2014-06-25, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ac13685437, moduleTitle=美国FDA一个月内批准的第二个抗菌素新药Sivextro预示抗生素新药研发的春天？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1ac13685437)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551361, encodeId=594f155136160, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA批准糖尿病管理平台手机应用, objectType=article, longId=35627, objectId=21ff3562e1d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21ff3562e1d, replyNumber=0, likeNumber=85, createdTime=2014-06-02, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21ff3562e1d, moduleTitle=美国FDA批准糖尿病管理平台手机应用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=21ff3562e1d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551360, encodeId=c464155136097, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=解读美国FDA关于临床研究监查的新指导原则, objectType=article, longId=27393, objectId=a26c2e393bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a26c2e393bb, replyNumber=0, likeNumber=82, createdTime=2013-12-02, rootId=0, userName=10518098zz, userId=a46914191431, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a26c2e393bb, moduleTitle=解读美国FDA关于临床研究监查的新指导原则, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a26c2e393bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551359, encodeId=9fa415513597d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=FDA：安斯泰来新药获美国FDA批准, objectType=article, longId=21910, objectId=c9712191049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9712191049, replyNumber=0, likeNumber=110, createdTime=2013-07-25, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9712191049, moduleTitle=FDA：安斯泰来新药获美国FDA批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c9712191049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551358, encodeId=59df15513585d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA新药审批速度和数量均超加拿大和欧洲, objectType=article, longId=6397, objectId=ccc7639e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccc7639e64, replyNumber=0, likeNumber=100, createdTime=2012-05-22, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccc7639e64, moduleTitle=美国FDA新药审批速度和数量均超加拿大和欧洲, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ccc7639e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1551357, encodeId=9b29155135e98, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, objectTitle=美国FDA增加密固达（唑来膦酸）新禁忌证, objectType=article, longId=3265, objectId=03d9326563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03d9326563, replyNumber=0, likeNumber=109, createdTime=2011-11-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03d9326563, moduleTitle=美国FDA增加密固达（唑来膦酸）新禁忌证, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=03d9326563)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

美国FDA

2020-05-29

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA一个月内批准的第二个抗菌素新药Sivextro预示抗生素新药研发的春天？

2014-06-25

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA批准糖尿病管理平台手机应用

2014-06-02

10518098zz (审核中...)

前往app查看评论内容

#美国FDA#

解读美国FDA关于临床研究监查的新指导原则

2013-12-02

zhaojie88 (审核中...)

前往app查看评论内容

#美国FDA#

FDA：安斯泰来新药获美国FDA批准

2013-07-25

zhaojie88 (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA新药审批速度和数量均超加拿大和欧洲

2012-05-22

zhaojie88 (审核中...)

前往app查看评论内容

#美国FDA#

美国FDA增加密固达（唑来膦酸）新禁忌证

2011-11-07

科室
- - 订阅+
  - 更多科室
工具
服务